Press release
MALT Lymphoma Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Discover the latest drugs and treatment options in the MALT Lymphoma Pipeline. Dive into DelveInsight's comprehensive report today! @ MALT Lymphoma Pipeline Outlook [https://www.delveinsight.com/sample-request/malt-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the MALT Lymphoma Pipeline Report
* In May 2025, Incyte Corporation announced a study is to evaluate the safety and efficacy of two parsaclisib treatment regimens in participants diagnosed with relapsed or refractory marginal zone lymphoma (MZL) who are naive to or were previously treated with a Bruton's tyrosine kinase (BTK) inhibitor.
* In May 2025, Regeneron Pharmaceuticals announced a study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back after treatment (called "relapsed"), or did not respond to treatment (called "refractory"). FL and MZL are subtypes of Non-Hodgkin 's lymphoma (NHL).
* In May 2025, BeiGene announced a study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular lymphoma (FL), as measured by progression-free survival as determined by an independent review committee in accordance with the 2014 modification of the International Working Group on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival (PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.
* DelveInsight's MALT Lymphoma Pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for MALT Lymphoma treatment.
* Promising MALT Lymphoma Companies such as MEI Pharma, Incyte, Genentech, BeiGene, Sound Biologics, ADC Therapeutics, Loxo Oncology and others.
* The leading MALT Lymphoma Pipeline Therapies such as Fludarabine, Rituximab, ibrutinib, milatuzumab, veltuzumab, Cytoxan and others.
Stay ahead with the most recent pipeline outlook for MALT Lymphoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ MALT Lymphoma Treatment Drugs [https://www.delveinsight.com/sample-request/malt-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
MALT Lymphoma Emerging Drugs Profile
* Tafasitamab: Incyte
Tafasitamab (MOR208) is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody directed against CD19 in clinical development for the treatment of B cell malignancies. Tafasitamab (MOR208, formerly Xmab Registered 5574) is an investigational monoclonal antibody directed against the antigen CD19 which is broadly expressed on the surface of B cells. It is therefore considered as a potential target for the treatment of B cell malignancies, such as non-Hodgkin's lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL), indolent lymphomas like follicular lymphoma (FL) and marginal zone lymphomas (MZL), as well as chronic lymphocytic leukemia (CLL). Tafasitamab (MOR208) binds to CD19. This antigen is broadly and homogeneously expressed across different B cell malignancies including diffuse large B cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). CD19 is able to enhance B cell receptor (BCR) signaling, which is important for B cell survival. Therefore, CD19 is considered a potential therapeutic target for drugs aimed at treating B cell-related lymphomas and leukemias. Currently the product is in Phase III stage of development for the treatment of Malt Lymphoma.
The MALT Lymphoma Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of MALT Lymphoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for MALT Lymphoma Treatment.
* MALT Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* MALT Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the MALT Lymphoma market
Explore groundbreaking therapies and clinical trials in the MALT Lymphoma Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New MALT Lymphoma Drugs [https://www.delveinsight.com/sample-request/malt-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
MALT Lymphoma Companies
MEI Pharma, Incyte, Genentech, BeiGene, Sound Biologics, ADC Therapeutics, Loxo Oncology and others.
Malt Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Small Molecule
* Gene Therapy
* Peptide
* Immunotherapy
* Cell Therapy
MALT Lymphoma Products have been categorized under various Molecule types such as
* Intravenous
* Intradermal
* Oral
* Subcutaneous
* Intramuscular
Unveil the future of MALT Lymphoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ MALT Lymphoma Market Drivers and Barriers [https://www.delveinsight.com/sample-request/malt-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the MALT Lymphoma Pipeline Report
* Coverage- Global
* MALT Lymphoma Companies- MEI Pharma, Incyte, Genentech, BeiGene, Sound Biologics, ADC Therapeutics, Loxo Oncology and others.
* MALT Lymphoma Pipeline Therapies- Fludarabine, Rituximab, ibrutinib, milatuzumab, veltuzumab, Cytoxan and others.
* MALT Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* MALT Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on MALT Lymphoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ MALT Lymphoma Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/malt-lymphoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Malt Lymphoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Malt Lymphoma - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Tafasitamab: Incyte
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Mosunetuzumab: Genentech
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* BGB-10188: BeiGene
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* PSB202: Sound Biologics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Malt Lymphoma Key Companies
* Malt Lymphoma Key Products
* Malt Lymphoma - Unmet Needs
* Malt Lymphoma - Market Drivers and Barriers
* Malt Lymphoma - Future Perspectives and Conclusion
* Malt Lymphoma Analyst Views
* Malt Lymphoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=malt-lymphoma-pipeline-appears-robust-with-10-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/malt-lymphoma-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release MALT Lymphoma Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4041299 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for Lymphoma
Lymphoma Treatment Market - Liberating Lives from Lymphoma: State-of-the-Art Tre …
Newark, New Castle, USA: The "Lymphoma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Lymphoma Treatment Market: https://www.growthplusreports.com/report/lymphoma-treatment-market/8879
This latest report researches the industry structure, sales, revenue,…
Lymphoma Treatment Market - Inspiring Resilience, Shaping Survival: Innovations …
Newark, New Castle, USA - new report, titled Lymphoma Treatment Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Lymphoma Treatment market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Lymphoma Treatment market. The report offers an overview of the market, which…
Lymphoma Therapeutics Market: New Frontiers in Lymphoma Therapeutics | By AMR
Allied Market Research recently said Lymphoma is a type of cancer that affects the lymphatic system, which is an integral part of the body's immune system. While chemotherapy and radiation therapy have been the standard treatment options for lymphoma, recent advances in research have led to the development of new targeted therapies and immunotherapies.
♦ 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.alliedmarketresearch.com/request-toc-and-sample/1448
One such targeted therapy is monoclonal antibodies, which can specifically target…
Daratumumab Market Precise Analysis , Forecast || key Players- Multiple Myeloma, …
Looking at the current market trends as well as the promising demand status of the “Daratumumab Market”, it can be projected that the future years will bring out positive outcomes. This research report added by Market Research Hub (MRH) on its online portal delivers clear insight about the changing tendencies across the global market. Readers can gather prime facets connected to the target market which includes product, end-use and application;…
T Cell Lymphoma Market T Cell Lymphoma Clinical Pipeline Report
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. T-Cell Lymphoma Market Analysis
2. Mechanism of T-Cell Lymphoma Therapeutics
3. T-Cell Lymphoma Drug Market Overview
3.1 Current Market Scenario
3.2 T Cell Lymphoma Clinical Pipeline Overview
4. T-Cell Lymphoma Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges
5. T-Cell Lymphoma Drug Market Future Prospects
6. T-Cell Lymphoma Drug Clinical Pipeline By Company…
B Cell Lymphoma Market B Cell Lymphoma Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to B Cell Lymphoma
1.1 Outline
1.1.1 Non-Hodgkin’s Lymphoma
1.1.2 Hodgkin’s Lymphoma
1.2 Classification of the B Cell lymphoma
1.2.1 Diffuse Large B Cell Lymphoma
1.2.2 Follicular Lymphoma
1.2.3 Mantle Cell Lymphoma
1.2.4 Burkitt Lymphoma
1.3 Stages of…
